Digital Technologies
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?
Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process
Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.
Amgen’s AI model to predict proteins in the “bright Goldilocks zone of viscosity” with over 80% accuracy minus a wet lab experiment holds immense potential, VP Research Haldar said at an event as he spoke about a “hinge moment” for AI in pharma
MSD's chief information & digital officer emphasizes the need for pharma to accelerate technology adoption cycles to ensure drugs reach patients faster. The role of a robust digital backbone for seamless data flow, leadership commitment in digital transformation and an upcoming technology center in Hyderabad are other aspects he discussed.
CEOs of top Indian firms discuss how policies and geopolitics could shape future manufacturing networks and also the simmering issue of tariffs. US President Donald Trump has just reiterated plans for reciprocal tariffs at a joint session of Congress.
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.
Legal heavyweights from Nishith Desai Associates, Anand and Anand, Corporate Law Group and EY partner and national cyber leader outline key compliance aspects that pharma and their global capability centers may need to factor as India moves to strengthen the framework for the protection of digital personal data.
Industry pundits talk about conversational AI for sales reps, the arrival of AI agents, a potential overhaul in the SaaS market for pharma enterprises and the tricky arena of influencer engagement in this instalment on key trends playing out on the tech front and in India. Expanding healthcare coverage is also improving the outlook for pharma in the country, they said.
More than 50 executives across industry share their expectations for the impact of AI on the biopharma industry over the coming year. While target identification and drug discovery featured highly, the opportunities to engage with patients and healthcare providers more effectively and the need for suitable regulatory frameworks were also flagged up.
PE firms Advent and Carlyle drove the biggest M&A deals in human and animal pharmaceuticals in India during 2024, a year that also saw Lupin strike deals with Eli Lilly and Boehringer Ingelheim to further its ambitions in the fast-growing diabetes space. Which segments look hot and what are the expected trends for deal making in 2025?
AI/ML is becoming increasingly widespread across the industry, but there are concerns about intellectual property that have arisen when most patent laws require inventors to be human.
The head of AI and automation in drug discovery at Merck KGaA’s life science business talked to Scrip about the company’s AI-powered platform that leverages a “gold mine” of proprietary R&D data, better in silico predictions and the next frontier of AI.
Merck’s India head for process solutions and Aragen Bioscience’s CEO talk about an incubator set-up and AI-led drug discovery to enable India’s research ecosystem, US tariffs on China, ADC and GLP-1 development, funding path for Goldman Sachs-investee Aragen and more in this video interview
Founder Ken Mulvany has returned to the artificial intelligence drug discovery specialist determined to ensure it plays to its “foundational strengths.” The UK firm has therefore initiated a major restructuring plan, along with the intention to delist from Euronext Amsterdam.
Deal Snapshot: December is just over a week old but the UK giant has packed a lot in, signing collaborations with likes of Duality Biologics (cancer) and Muna Therapeutics (neurodegeneration). Now it is targeting fibrotic diseases and osteoarthritis after inking a deal with Relation Therapeutics.
Primary biliary cholangitis or cirrhosis, PBC, is a lesser-known cousin of MASH but a silent killer, nevertheless. Scrip studies data from Citeline’s Pharmaprojects and separately Evaluate Pharma to reveal a promising pipeline and drug revenue forecasts, with APAC firms accounting for half the pipeline of drugs
The Swiss major’s chief medical officer tells Scrip about how “an R&D/commercial continuum” is helping to speed up innovation across the group.